Objectives Brivaracetam (BRV) is the latest approved antiepileptic drug and acts as a synaptic vesicle protein 2A ligand. The aim of the present study was to evaluate the efficacy and tolerability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback